Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results.

Biomea’s management will host a conference call and webcast on Tuesday, October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT). The live webcast will be accessible through the Investors and Media section of the Company’s website at https://investors.biomeafusion.com/news-events/events. A replay will be available on the Company’s website following the event.